Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

Agustin L Gonzalez Eye & Vision, Richardson, TX 75082, USA Purpose: The aim of this study was to evaluate the safety and efficacy of lifitegrast 5% ophthalmic solution in improving contact lens discomfort (CLD) in patients wearing a low-modulus, nonionic, monthly replacement silicone hydro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gonzalez AL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Lifitegrast contact lens discomfort dry eye contact lens discontinuation Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/02a29351a4ee4d0482f7c4c08b56ac35
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:02a29351a4ee4d0482f7c4c08b56ac35
record_format	dspace
spelling	oai:doaj.org-article:02a29351a4ee4d0482f7c4c08b56ac352021-12-02T07:05:51ZSafety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort1177-5483https://doaj.org/article/02a29351a4ee4d0482f7c4c08b56ac352018-10-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-lifitegrast-5-ophthalmic-solution-in-contact-le-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Agustin L Gonzalez Eye & Vision, Richardson, TX 75082, USA Purpose: The aim of this study was to evaluate the safety and efficacy of lifitegrast 5% ophthalmic solution in improving contact lens discomfort (CLD) in patients wearing a low-modulus, nonionic, monthly replacement silicone hydrogel contact lenses (SHCLs). Patients and methods: A single center, prospective, open-label study was undertaken on patients wearing monthly replacement, low modulus silicone hydrogel contact lenses. Best-corrected visual acuity (BVA), lissamine staining (LS) and eight item contact lens dry eye questionnaire (CLDEQ-8) scores were assessed at baseline and after 8-week therapy of twice-a-day lifitegrast 5% ophthalmic solution use. Pre- and Posttreatment data were analyzed for statistical significance. Results: Twenty-one subjects (15 female and six male) with the mean age of 31.7 (±5.29) years completed the study. No reduction or statistically significant change in monocular BVA or LS scores was observed. Data showed a statistically significant (P<0.05) reduction in total CLDEQ-8 score, questions 1A, 1B, 2A and 2B scores and nonstatistically significant reduction in questions 3A, 3B, 4 and 5 scores. Fifteen (n=15, 71.4%) study subjects found the therapy positive for their contact lens wear. Conclusion: Data suggest the use of topical lifitegrast 5% ophthalmic solution twice a day may be a safe and effective therapeutic intervention for managing patients with CLD in SHCL users; however further research is indicated. Keywords: lifitegrast, contact lens discomfort, dry eye, contact lens discontinuationGonzalez ALDove Medical PressarticleLifitegrastcontact lens discomfortdry eyecontact lens discontinuationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2079-2085 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lifitegrast contact lens discomfort dry eye contact lens discontinuation Ophthalmology RE1-994
spellingShingle	Lifitegrast contact lens discomfort dry eye contact lens discontinuation Ophthalmology RE1-994 Gonzalez AL Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
description	Agustin L Gonzalez Eye & Vision, Richardson, TX 75082, USA Purpose: The aim of this study was to evaluate the safety and efficacy of lifitegrast 5% ophthalmic solution in improving contact lens discomfort (CLD) in patients wearing a low-modulus, nonionic, monthly replacement silicone hydrogel contact lenses (SHCLs). Patients and methods: A single center, prospective, open-label study was undertaken on patients wearing monthly replacement, low modulus silicone hydrogel contact lenses. Best-corrected visual acuity (BVA), lissamine staining (LS) and eight item contact lens dry eye questionnaire (CLDEQ-8) scores were assessed at baseline and after 8-week therapy of twice-a-day lifitegrast 5% ophthalmic solution use. Pre- and Posttreatment data were analyzed for statistical significance. Results: Twenty-one subjects (15 female and six male) with the mean age of 31.7 (±5.29) years completed the study. No reduction or statistically significant change in monocular BVA or LS scores was observed. Data showed a statistically significant (P<0.05) reduction in total CLDEQ-8 score, questions 1A, 1B, 2A and 2B scores and nonstatistically significant reduction in questions 3A, 3B, 4 and 5 scores. Fifteen (n=15, 71.4%) study subjects found the therapy positive for their contact lens wear. Conclusion: Data suggest the use of topical lifitegrast 5% ophthalmic solution twice a day may be a safe and effective therapeutic intervention for managing patients with CLD in SHCL users; however further research is indicated. Keywords: lifitegrast, contact lens discomfort, dry eye, contact lens discontinuation
format	article
author	Gonzalez AL
author_facet	Gonzalez AL
author_sort	Gonzalez AL
title	Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
title_short	Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
title_full	Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
title_fullStr	Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
title_full_unstemmed	Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
title_sort	safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/02a29351a4ee4d0482f7c4c08b56ac35
work_keys_str_mv	AT gonzalezal safetyandefficacyoflifitegrast5ophthalmicsolutionincontactlensdiscomfort
_version_	1718399555594092544

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

Ejemplares similares